GPT and chronic hepatitis C virus infection: Successively, another trial by the same group was designed to assess the relationship between the dose and the effect of bLf on serum ALT and HCV RNA levels in forty-five patients with chronic hepatitis C who orally received 1.8, 3.6, and 7.2 g/day bLf for 8-weeks [171].